Hypoxic-Ischemic Encephalopathy (HIE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Hypoxic-Ischemic Encephalopathy (HIE) Market Outlook

Thelansis’s “Hypoxic-Ischemic Encephalopathy (HIE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypoxic-Ischemic Encephalopathy (HIE)  treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypoxic-Ischemic Encephalopathy (HIE) Overview

Hypoxic-Ischemic Encephalopathy (HIE)-ischemic encephalopathy (HIE) is a neurological syndrome that presents immediately after birth after a perinatal asphytic episode. It occurs due to oxygen deprivation in the brain, arterial hypoxemia or cerebral ischemia, or both. Alterations in alertness characterize it, with decreased ability to awaken and maintain muscle tone, reduced motor responses, and reactivity. HIE is a leading cause of neonatal death and permanent disability. It contributes significantly to the health burden regarding years of life lost and years lived with disability. In addition to the critical role that asphyxia plays in perinatal mortality, it is estimated that over one million newborns who survive it each year develop cerebral palsy, epilepsy, learning disabilities, and other developmental problems. It is currently the only standard therapy for HIE and is a safe and effective intervention for reducing mortality and significant disability in survivors.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Hypoxic-Ischemic Encephalopathy (HIE)  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034